AstraZeneca sells IBD drug for $215M; Seattle Genetics launches PhII Adcetris study;

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Female libido drug lobbying sparks a backlash as FDA decision looms. Story | Follow @JohnCFierce

@DamianFierce: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Press release | Follow @DamianFierce

> AstraZeneca is selling ex-U.S. rights to its IBD drug Entocort (budesonide) from AstraZeneca for $215 million in cash. Release

> Seattle Genetics has launched a Phase II clinical trial evaluating Adcetris (brentuximab vedotin) in systemic lupus erythematosus. Release

> Australia's Benitec has acquired full rights to a pre-clinical hepatitis B program from China's Biomics Biotechnologies, which had been working with Benitec in a joint venture. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Brain scan can be used to distinguish between traumatic brain injury and PTSD. Article | Follow @FierceMedDev

@EmilyWFierce: Sunshine Act payment data leaves out newly influential prescribers. More from FiercePharma | Follow @EmilyWFierce

> One year after IPO, Intersect ENT still going strong--starts pivotal testing, raises $103M. Story

> Not quite profitable, IPO star K2M cashes out investors with $177M in 2015. Report

Pharma News

@FiercePharma: U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: Here's the latest episode of @FierceBiotech radio--and it even comes endorsed by @brentlsaunders! (He's real.) Listen | Follow @CarlyHFierce

> Payers think they can squeeze prices on cancer immunotherapies? Not so fast, analyst says. Story

> BMJ: Pfizer, Allergan antidepressants show no links to birth defects. Report

Vaccines News

> Shantha's cholera jab prevents 37% of cholera cases in Bangladeshi study. More

> Poll: parents view vaccines as safer, more beneficial. Item

> J&J's HIV vaccine shows promise in monkeys; PhI/IIa to start soon. Article

> NIAID launches PhI trial of investigational West Nile virus vaccine. Story

> U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine. Report

CRO News

> Recipharm takes a 25% stake in its drug-developing partner. Item

> Parexel uses virtual clinical trials to improve real-life R&D. Report

> Charles River spends $212M to beef up its microbial testing. Story

> BioClinica buys a patient recruitment firm to bolster study startup. Article

Pharma Manufacturing News

> Twitter chat redux: In case you missed the chat, we don't want you to miss the info. More

> India may use FDA as model for bolstering its oversight. Item

> Lupin antibiotic products banned by Brazil. Story

> Chinese staffer key to negotiating deal to bolster FDA staff in China. Report

> FDA sends drugmakers warning letters reminding them to pay up. Article

Pharma Asia News

> India's Lupin hit by Brazil regulator suspension of antibiotic API. News

> Drug firms in Australia to report gifts to doctors starting Oct. 1, ABC says. Item

> India aims at U.S. FDA standards on drugs with name change afoot. Report

> Watch out AbbVie, Samsung Bioepis does fine with Humira biosimilar in PhIII. Story

> Israel's Oramed says $50M oral insulin deal with Sinopharm Capital-Hefei, not Guangxi Wuzhou. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.